Acquacalda E, Roux CH, Albert C, Breuil V, Passeron T, Euller-Ziegler L
Joint Bone Spine 2015 Mar;
OBJECTIVES: Severe hidradenitis suppurativa (HS), under infliximab, can be associated with different forms of arthritis whose mechanism is unclear. Our objective is to establish the frequency and clinical presentation of new-onset arthritis in HS under infliximab.
METHODS: Severe HS patients under infliximab were followed up between 2007-2012. New articular inflammatory manifestations were investigated by rheumatologist.
RESULTS: Three patients over eleven developed a polyarthritis. Mean duration of arthritis was 3 months. At treatment’s stop: 2 patients improved and 1 relieved with adalimumab.
CONCLUSION: The inflammatory rheumatism’s frequency in HS under infliximab seems underestimated.